Siemens Builds a Rail Case in Taiwan and Britain While Preparing to Let Healthineers Go

Siemens is asking investors to judge two very different stories at once: a rail business that is expanding through acquisitions, new facilities and long-dated contracts, and a corporate restructuring that will see Siemens Healthineers uncoupled from the group in 2027. How convincingly the company can run both tracks simultaneously is emerging as the central question for shareholders.

The rail push has three visible pillars. Siemens Mobility opened a rail infrastructure and innovation centre in Chippenham on Friday, a project the company values at EUR 115 million and says safeguards 800 local jobs. On 4 November, having secured all required approvals, it completed the purchase of key business units from Italy's MERMEC Group, covering rail signalling, electrification, telecommunications and diagnostics. A day later came signalling orders from ST Engineering Urban Solutions for the Brown Line and the Green Line extension of Taiwan's Metro Taoyuan, including GoA4 full automation.

Those Taoyuan contracts give the expansion a concrete project anchor. Revenue, however, will not arrive quickly: the new sections are scheduled to enter service in the mid-2030s, which stretches the investment horizon across roughly a decade. Shareholders with that kind of patience may read the orders as evidence of a durable project base; those with shorter horizons will note that the gap between signature and commissioning leaves plenty of room for cost overruns and delays.

The Chippenham spend and the MERMEC businesses are best assessed together rather than as separate headlines. Capital outlays create capacity, but their economic worth only shows up in execution — whether the acquired signalling, electrification and diagnostics capabilities can be folded into day-to-day project work. A broader technical footprint should help Siemens Mobility handle complex rail schemes, though the company has not said that any specific MERMEC unit will be deployed on the Taoyuan work.

Should investors sell immediately? Or is it worth buying Siemens?

Integration is the risk that sits underneath the optimism. If the new units prove hard to combine, whether organisationally or technically, the expansion raises the operational bar instead of lowering it. The same logic applies to the long project timelines: tasks that consume more resources than planned would push the payoff further into the future.

Running alongside all this is the restructuring. Siemens said on 5 November that it will deconsolidate Siemens Healthineers through a spin-off in 2027, after which the business is to trade simply as Healthineers. Shareholders of both companies are to vote on the move at their annual general meetings in February 2027 — the next fixed checkpoint on the calendar, and one that will shape the group's future structure. The renaming likewise requires approval from the Healthineers AGM.

Buybacks continue in the meantime. Siemens reported on Monday that it repurchased about 360,000 of its own shares between 2 and 8 November inclusive, taking the total bought back under the programme to roughly 5.94 million since 1 July through the end of that reporting period.

One more deal remains to be closed. The acquisition of Lauterbach, agreed earlier, is expected to complete in the first half of 2027, subject to customary conditions and regulatory clearance.

Taken together, the picture comes down to execution. Should Siemens keep the rail expansion moving and prepare the spin-off in an orderly fashion, the constructive case holds. If integration and restructuring start to compete for the same management attention, valuation will lean more heavily on progress actually delivered — and further announcements will carry less weight than the work already on the books.

Ad

Siemens Stock: New Analysis - 11 November

Fresh Siemens information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Siemens analysis...